Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

Kathia De Man; Sarah Piron; Nick Van Laeken; Louke Delrue; Valérie Fonteyne; Nicolaas Lumen; Bliede Van den Broeck; Ken Kersemans; Piet Ost; Vanessa Schelfhout

doi:10.1007/s11307-022-01724-2

Impact of ¹⁸F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : ¹⁸F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

Mol Imaging Biol. 2022 Oct;24(5):750-758. doi: 10.1007/s11307-022-01724-2. Epub 2022 Apr 11.

Authors

Affiliations

¹ Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium. [email protected].
² Laboratory of Radiopharmacy, Ghent University, Ghent, Belgium.
³ Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.
⁴ Department of Medical Imaging, Radiology, Ghent University Hospital, Ghent, Belgium.
⁵ Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium.
⁶ Department of Urology, Ghent University Hospital, Ghent, Belgium.
⁷ Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
⁸ Department of Radiation-Oncology, Iridium Network, Wilrijk, Belgium.

PMID: 35411446
DOI: 10.1007/s11307-022-01724-2

Abstract

Purpose: In this study, we evaluated the impact of ¹⁸F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed.

Procedures: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with ¹⁸F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the ¹⁸F-PSMA-11 findings.

Results: The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on ¹⁸F-PSMA-11 PET/CT.

Conclusion: ¹⁸F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions.

Keywords: 18F-PSMA-11; Human; Management; PET/CT; Prostate cancer.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Gallium Radioisotopes
Humans
Male
Neoplasm Recurrence, Local / diagnostic imaging
Positron Emission Tomography Computed Tomography* / methods
Prospective Studies
Prostate-Specific Antigen
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / therapy

Substances

Prostate-Specific Antigen
(18)F-PSMA-11
Gallium Radioisotopes